Related Experiment Video
Updated: Apr 14, 2026
Methodology for Accurate Detection of Mitochondrial DNA Methylation
Published on: May 20, 2018
Platelet mitochondrial DNA methylation: a potential new marker of cardiovascular disease
Andrea A Baccarelli1, Hyang-Min Byun2
1Laboratory of Environmental Epigenetics, Exposure Epidemiology and Risk Program, Department of Environmental Health, Harvard T.H. Chan School of Public Health, 677 Huntington Ave., Boston, MA 02115 USA.
Insights
Platelet mitochondrial DNA (mtDNA) methylation is elevated in cardiovascular disease (CVD) patients. This epigenetic marker, found in mitochondrial genes crucial for ATP synthesis, may play a role in CVD development.
Area of Science:
- Epigenetics
- Mitochondrial Biology
- Cardiovascular Disease Research
Background:
- Platelets are vital in cardiovascular disease (CVD) pathogenesis.
- Mitochondria provide energy for platelet function.
- Epigenetic factors like DNA methylation are CVD markers, but mitochondrial DNA (mtDNA) methylation is understudied.
Purpose of the Study:
- To investigate platelet mitochondrial DNA (mtDNA) methylation.
- To explore the association between platelet mtDNA methylation and CVD.
Main Methods:
- Measured platelet mtDNA methylation using bisulfite-PCR pyrosequencing.
- Examined methylation in specific mitochondrial genes (MT-CO1, MT-CO2, MT-CO3, MT-TL1, MT-ATP6, MT-ATP8, MT-MD5).
Main Results:
- CVD patients showed significantly higher mtDNA methylation in MT-CO1, MT-CO2, MT-CO3, and MT-TL1 compared to controls.
- These genes are involved in ATP synthesis.
- Platelet mtDNA methylation levels were not associated with age, BMI, or race.
Conclusions:
- Platelet mtDNA methylation may be implicated in the etiology of CVD.
- This epigenetic marker could serve as a non-invasive and easily obtainable biomarker for CVD.
Background:
Platelets are critical in the etiology of cardiovascular disease (CVD), and the mitochondria in these cells serve as an energy source for platelet function. Epigenetic factors, especially DNA methylation, have been employed as markers of CVD. Unlike nuclear DNA methylation, mitochondrial DNA (mtDNA) methylation has not been widely studied, in part, due to debate about its existence and role. In this study, we examined platelet mtDNA methylation in relation to CVD.
Results:
We measured mtDNA methylation in platelets by bisulfite-PCR pyrosequencing and examined associations of CVD with methylation in mitochondrial genes; cytochrome c oxidase (MT-CO1, MT-CO2, and MT-CO3); tRNA leucine 1 (MT-TL1); ATP synthase (MT-ATP6 and MT-ATP8); and NADH dehydrogenase (MT-MD5). We report that CVD patients have significantly higher mtDNA methylation than healthy controls in MT-CO1 (18.53%, P < 0.0001), MT-CO2 (3.33%, P = 0.0001), MT-CO3 (0.92%, P < 0.0001), and MT-TL1 (1.67%, P = 0.0001), which are involved in ATP synthesis. Platelet mtDNA methylation was not related with age, BMI, and race in this study.
Conclusions:
Our results suggest that platelet mtDNA methylation, which could serve as non-invasive and easy-to-obtain markers, may be implicated in the etiology of CVD.
Related Concept Videos
02:59Animal Mitochondrial Genetics
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...